UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 高血圧治療におけるレニン・アンギオテンシン系阻害renin angiotensin system inhibition in the treatment of hypertension [show details]
… renin-angiotensin system (RAS), particularly angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), are commonly used in the treatment of hypertension. The role of the RAS …
2. 駆出率低下を伴う心不全へのアンジオテンシンII受容体拮抗薬の使用use of angiotensin ii receptor blocker in heart failure with reduced ejection fraction [show details]
… on and use of ARB therapy in HFrEF. The role of angiotensin receptor-neprilysin inhibitor therapy in HFrEF, an overview of pharmacologic treatment of HFrEF, and mechanisms of action of ARB therapy are discussed …
3. 駆出率低下を伴う心不全へのアンジオテンシン変換酵素阻害薬の使用use of angiotensin converting enzyme inhibitors in heart failure with reduced ejection fraction [show details]
… consultation is present. An ACE inhibitor should not be prescribed for patients with idiopathic or heritable angioedema or angioedema related to prior ACE inhibitor use. ACE inhibitor use in the following clinical …
4. 成人の非糖尿病性慢性腎臓病患者に対する降圧療法と病状の進展antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults [show details]
… similar renoprotective effect as ACE inhibitors in nondiabetic CKD but supportive data are limited . Studies in humans have found that ARBs are as effective as ACE inhibitors in reducing protein excretion …
5. アンギオテンシン変換酵素阻害剤およびアンギオテンシンII受容体拮抗剤の主な副作用major side effects of angiotensin converting enzyme inhibitors and angiotensin ii receptor blockers [show details]
… Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are widely used in the treatment of hypertension, chronic kidney disease, and heart failure. In addition to efficacy …

English Journal

Differences in biomarkers of crack-cocaine adolescent users before/after abstinence.

Pianca TG, Rosa RL, Ceresér KMM, de Aguiar BW, de Abrahão RC, Lazzari PM, Kapczinski F, Pechansky F, Rohde LA, Szobot CM.
Drug and alcohol dependence. 2017 08;177()207-213.
To measure the variation in Brain-Derived Neurotrophic Factor (BDNF), Thiobarbituric Acid Reactive Substances (TBARS) and interleukin (IL) levels in crack-cocaine dependent adolescents after 21days of abstinence, comparing to levels found in a group of healthy controls. Cross-sectional nested on a s
PMID 28618284

Crack Cocaine Use in Adolescents: Clinical Characteristics and Predictors of Early Initiation.

Pianca TG, Rohde LA, Rosa RL, Begnis AP, Ferronatto PB, Jensen MC, Pechansky F, Ceresér KM, Fairchild VP, Szobot CM.
The Journal of clinical psychiatry. 2016 Oct;77(10)e1205-e1210.
To describe the clinical characteristics of adolescents with crack cocaine dependence and possible predictors of transition from drug experimentation to crack cocaine dependence. This cross-sectional study enrolled a consecutive sample of 90 adolescents admitted to a psychiatric inpatient unit in th
PMID 27574840

Neurofunctional changes in adolescent cannabis users with and without bipolar disorder.

Bitter SM, Adler CM, Eliassen JC, Weber WA, Welge JA, Burciaga J, Shear PK, Strakowski SM, DelBello MP.
Addiction (Abingdon, England). 2014 Nov;109(11)1901-9.
To compare regional brain activation among adolescents with bipolar disorder and co-occurring cannabis use disorder. Cross-sectional study. Cincinnati, OH, USA. Adolescents with bipolar disorder (BP, n = 14), adolescents with cannabis use disorder (MJ, n = 13), adolescents with co-occurring
PMID 24962329